AI
HALO icon

Analytic Investors’s Halozyme HALO Stock Holding History

Analytic Investors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-75,651
Closed -$653K – 624
2016
Q2 		$653K Buy
75,651
+353
+0.5% +$3.48K 0.01% 432
2016
Q1 		$713K Sell
75,298
-20,080
-21% -$189K 0.01% 443
2015
Q4 		$1.65M Buy
95,378
+36,378
+62% +$580K 0.02% 320
2015
Q3 		$792K Buy
+59,000
New +$1.18M 0.01% 398

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Analytic Investors's HALO Position: Q3 2016 in Review

Analytic Investors sold out of Halozyme (HALO) in Q3 2016, closing a stake of 75,651 shares — an estimated $653K sold.

Analytic Investors first reported a position in HALO in Q3 2015 and held it in 4 quarters. The position peaked at $1.65M in Q4 2015. 162 funds tracked by Wall St. Rank hold HALO as of Q3 2016.

  • Analytic Investors reported no remaining Halozyme position as of Q3 2016 after selling out during the quarter.
  • Analytic Investors sold 75,651 Halozyme shares in Q3 2016, an estimated $653K.
  • Analytic Investors first reported a position in Halozyme in Q3 2015 and held it in 4 quarters.
  • Analytic Investors's Halozyme position peaked at $1.65M in Q4 2015.
  • 162 funds tracked by Wall St. Rank held Halozyme as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.